MONTREAL--(BUSINESS WIRE)--Angiochem, Inc. today announced its plans for advancing the development of product candidates from its pipeline, using the company’s proprietary platform for Engineered Peptide Compounds (EPiC) for drugs that cross the blood-brain barrier through LRP-1 targeting. The product candidates cover a range of therapeutic areas, including pain, obesity and Parkinson’s disease, using Angiochem’s technology to uniquely enable drugs to penetrate the CNS, including biologics (peptides and proteins) and small molecules. In addition, Angiochem will continue to actively pursue additional research and development collaborations.
